Table 1.
Patient characteristics
| Patient characteristics | First 60 (n = 60) | Total (n = 140) | P-value |
|---|---|---|---|
| Age (years), mean ± standard deviation | 76.8 ± 9.9 | 77.0 ± 10.2 | 0.84 |
| Male, n (%) | 37 (61.7) | 85 (60.7) | 0.86 |
| Pacing indication, n (%) | |||
| Symptomatic sinus node dysfunction | 20 (33.3) | 40 (28.6) | 0.35 |
| 2nd-degree AV block | 4 (6.7) | 8 (5.7) | 0.72 |
| 3rd-degree AV block | 6 (10.0) | 11 (7.9) | 0.53 |
| SND + AV block | 1 (1.7) | 2 (1.4) | 1.00 |
| AV block with persistent/permanent arrhythmias | 28 (46.7) | 72 (51.4) | 0.39 |
| Other indication | 1 (1.7) | 7 (5.0) | 0.24 |
| Reason for selecting single-chamber pacemaker, n (%) | |||
| Indications associated with persistent/permanent/chronic atrial tachyarrhythmias | 34 (56.7) | 82 (58.6) | 0.73 |
| Frequent pacing not expected | 21 (35.0) | 45 (32.1) | 0.59 |
| Patients advanced age | 5 (8.3) | 18 (12.9) | 0.21 |
| Significant co-morbities affecting survival and clinical outcome | 2 (3.3) | 3 (2.1) | 0.58 |
| Previous planned AV nodal ablation | 0 (0.0) | 2 (1.4) | 0.51 |
| Patients expected to be sedentary | 2 (3.3) | 5 (3.6) | 1.00 |
| Patient's anatomy precludes placement of atrial lead | 1 (1.7) | 2 (1.4) | 1.00 |
| Dual-chamber pacing complication risk deemed to high | 0 (0.0) | 1 (0.7) | 1.00 |
| Other reason | 2 (3.3) | 8 (5.7) | 0.24 |
| Cardiac disease, n (%) | |||
| Cardiomyopathy, dilated/congestive + Cardiomyopathy, ischaemic | 5 (8.3) | 5 (3.5) | 0.01 |
| Coronary artery disease + Myocardial infarction | 20 (33.3) | 44 (31.4) | 0.72 |
| Pulmonary hypertension | 1 (1.7) | 7 (5.0) | 0.24 |
| Valve dysfunction, tricuspid | 10 (16.7) | 23 (16.4) | 1.00 |
| Hypertension | 46 (76.7) | 111 (79.3) | 0.53 |
| Symptoms, n (%) | |||
| Congestive heart failure | 5 (8.3) | 13 (9.3) | 0.78 |
| Syncope | 23 (38.3) | 55 (39.3) | 0.86 |
| Comorbidities (%) | |||
| Diabetes | 17 (28.3) | 34 (24.3) | 0.43 |
| Renal dysfunction | 10 (16.7) | 26 (18.6) | 0.67 |
| Chronic obstructive pulmonary disease (COPD) | 4 (6.7) | 14 (10.0) | 0.39 |
| Implant success rate (%) | 60 (100.0) | 140 (100.0) | 1.00 |
| Procedure duration (min) | |||
| Mean ± standard deviation | 37.9 ± 24.8 | 36.7 ± 20.7 | 0.54 |
| Fluoroscopy duration (min) | |||
| Mean ± standard deviation | 10.1 ± 7.8 | 9.1 ± 7.0 | 0.18 |
| Redeployments, n (%) | |||
| 0 | 34 (56.7) | 82 (58.6) | 0.76 |
| 1–4 | 24 (40.0) | 52 (37.1) | |
| ≥5 | 2 (3.3) | 6 (4.3) | |
| Hours to ambulation following procedure | |||
| Mean ± standard deviation | 14.7 ± 7.6 | 13.1 ± 8.5 | 0.10 |
P-value is from the t-test (continuous variables) or Fisher Exact test (categorical variables) comparing those in the early performance cohort (first 60 implanted) to those implanted later.